FDA Panel: Concerns Over PI3K Inhibitors in Blood Cancers

An FDA advisory panel voted in favor of using randomized trials of PI3K drugs instead of single-arm studies in blood cancer studies, because of concerns about toxicities in this class of drugs.
Medscape Medical News
An FDA advisory panel voted in favor of using randomized trials of PI3K drugs instead of single-arm studies in blood cancer studies, because of concerns about toxicities in this class of drugs.
Medscape Medical News